Aclarion Business Summary

Aclarion, Inc. (ACON) is a commercial-stage healthcare technology company that operates a software-native business model centered on its proprietary Nociscan platform. The company generates revenue through a transactional SaaS model, charging for non-invasive diagnostic reports that utilize Magnetic Resonance Spectroscopy (MRS) and augmented intelligence (AI) algorithms to identify biochemical biomarkers of discogenic low back pain. Primary business segments include clinical diagnostic services for physicians and imaging centers, alongside a growing clinical trial segment supporting its pivotal 300-patient CLARITY trial. Aclarion differentiates itself from traditional hardware-centric medical device firms by delivering its solution entirely through the cloud, enabling software-level gross margins and rapid global scalability. Its primary competitors include Mangoceuticals (MGRX), Biotricity (BTCY), and Healthcare Triangle (HCTI); Aclarion occupies a specialized niche as the only provider of objective, biochemical decision-support tools for spinal surgery planning. The leadership team is anchored by Executive Chairman and Founder Jeff Thramann, MD, a neurosurgeon and serial entrepreneur who previously founded Auddia Inc. and Lanx, LLC. Chief Executive Officer Brent Ness, appointed in 2021, brings over 25 years of medtech experience from roles at Cleerly and Mighty Oak Medical, while Chief Financial Officer Greg Gould, who joined in September 2025, provides a 30-year track record of raising over $450 million in public capital. The executive suite is rounded out by Chief Strategy Officer Ryan Bond, who oversees commercial expansion and clinical validation efforts. Notable institutional and insider support includes NuVasive, Inc., which remains a significant shareholder, and a board featuring Lead Independent Director William Wesemann and David Neal. As of February 2026, the company maintains a debt-free balance sheet with a cash runway extending into 2028 following a successful $10.4 million financing round in early 2026.